AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+/HER2− primary breast cancer.

Authors

Mario Campone

Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France

Mario Campone , Yvonne Dong , Bethany Ling , Lei Wang , Christina Isabella Herold

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.

First Author: Aditya Bardia

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

First Author: Sarat Chandarlapaty

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.

First Author: Shanshan Chen

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II preoperative window study of SAR439859 versus letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

First Author: Mario Campone